- Home
- GLDD vs CRGX Comparison
GLDD vs CRGX Comparison
Compare GLDD & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLDD
- CRGX
- Stock Information
- Founded
- GLDD 1890
- CRGX 2021
- Country
- GLDD United States
- CRGX United States
- Employees
- GLDD N/A
- CRGX N/A
- Industry
- GLDD Military/Government/Technical
- CRGX
- Sector
- GLDD Industrials
- CRGX
- Exchange
- GLDD Nasdaq
- CRGX Nasdaq
- Market Cap
- GLDD 829.6M
- CRGX 964.5M
- IPO Year
- GLDD 2006
- CRGX 2023
- Fundamental
- Price
- GLDD $11.94
- CRGX $16.00
- Analyst Decision
- GLDD Buy
- CRGX Strong Buy
- Analyst Count
- GLDD 1
- CRGX 7
- Target Price
- GLDD $14.00
- CRGX $30.33
- AVG Volume (30 Days)
- GLDD 445.8K
- CRGX 167.8K
- Earning Date
- GLDD 11-05-2024
- CRGX 11-12-2024
- Dividend Yield
- GLDD N/A
- CRGX N/A
- EPS Growth
- GLDD N/A
- CRGX N/A
- EPS
- GLDD 0.87
- CRGX N/A
- Revenue
- GLDD $741,648,000.00
- CRGX N/A
- Revenue This Year
- GLDD $31.75
- CRGX N/A
- Revenue Next Year
- GLDD $7.25
- CRGX N/A
- P/E Ratio
- GLDD $13.68
- CRGX N/A
- Revenue Growth
- GLDD 33.74
- CRGX N/A
- 52 Week Low
- GLDD $6.40
- CRGX $13.56
- 52 Week High
- GLDD $12.83
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- GLDD 52.24
- CRGX 32.69
- Support Level
- GLDD $10.25
- CRGX $19.96
- Resistance Level
- GLDD $12.83
- CRGX $23.00
- Average True Range (ATR)
- GLDD 0.49
- CRGX 1.79
- MACD
- GLDD -0.04
- CRGX -0.58
- Stochastic Oscillator
- GLDD 65.31
- CRGX 7.04
About GLDD Great Lakes Dredge & Dock Corporation
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.